Spondyloarthritis Explained

Synonyms:Spondyloarthropathy

Spondyloarthritis (SpA), also known as spondyloarthropathy, is a collection of clinical syndromes that are connected by genetic predisposition and clinical manifestations.[1] The best-known clinical subtypes are enteropathic arthritis (EA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and reactive arthritis (ReA). Spondyloarthritis typically presents with inflammatory back pain and asymmetrical arthritis, primarily affecting the lower limbs, and enthesitis, inflammation at bone-adhering ligaments, tendons, or joint capsules.

Spondyloarthritis is caused by a combination of genetic polymorphisms and environment, with the relative contributions of genes and environment varying across different types. It is associated with ileal inflammation, with an immunological connection between Crohn's disease and ankylosing spondylitis. Reactive arthritis is primarily caused by gastrointestinal pathogens, genitourinary and respiratory infections, and genetic variables. HLA-B27, a polymorphic form of the HLA-B molecule, is found in up to 95% of European spondylitis patients, 70% having reactive arthritis, 60% with psoriatic spondylitis, 25% with peripheral psoriatic arthritis, and 70% with spondylitis associated with inflammatory bowel disease.

The arthritogenic-peptide theory suggests that HLA-B27 displays self-peptides that resemble pathogen-derived peptides to CD8-restricted T cells. Two other theories suggest that HLA-B27's genesis may be autoinflammatory, initiating innate immune responses instead of presenting antigens. The first hypothesis suggests that HLA-B27 heavy chains without β2 microglobulin can form disulphide-linked homodimers, recognized by KIR3DL2 killer immunoglobulin-like receptors. The second hypothesis suggests that the B pocket's Cys 67 residue causes HLA-B27 heavy-chain misfolding, modifying immune cells' cytokine output and reactivity to innate immunological stimuli.

Spondyloarthritis is diagnosed based on clinical factors, including inflammatory back pain, limited spinal mobility, and radiological sacroiliitis, though many patients may not have radiographic evidence of sacroiliitis for up to 10 years. Early diagnosis criteria consider HLA-B27 testing and MRI scanning advancements. Spondyloarthritis is categorized into two groups based on the Assessment of SpondyloArthritis International Society (ASAS) criteria: primarily axial involvement and predominantly peripheral manifestations.

Non-steroidal anti-inflammatory drugs (NSAIDs) should be administered first for active axial signs of spondyloarthritis. If NSAIDs are contraindicated or cause side effects, TNF blockers should be used. Traditional disease-modifying antirheumatic drugs (DMARDs) are not advised for patients without peripheral disease signs.

The prevalence of ankylosing spondylitis and spondyloarthritis varies across populations. The incidence of spondyloarthritis was recorded in four investigations, with a range of 0.48/100,000 in Japan to 62.5/100,000 in Spain.

Signs and symptoms

In all subtypes of spondyloarthritis, inflammatory back pain and/or asymmetrical arthritis, mainly affecting the lower limbs, are the most common symptoms.[2] Another distinguishing characteristic is enthesitis, which is inflammation at the locations where ligaments, tendons, or joint capsules adhere to bone.[3] Inflammatory back pain associated with ankylosing spondylitis usually starts slowly, has a dull feel to it, and spreads into the gluteal areas. Back pain has a nocturnal component, gets better with movement, and is worse in the morning. Axial arthritis may begin in the sacroiliac joints and work its way up to the cervical spine over time. Spinal abnormalities such as flattening of the lumbar lordosis, exaggeration of the thoracic kyphosis, and hyperextension of the cervical spine lead to limited spinal motion. Hip and shoulder arthritis can occur in certain ankylosing spondylitis patients, usually early in the course of the illness. Usually, the other peripheral joints start to suffer later. Most frequently, there is an asymmetrical involvement of the lower extremities.

Reactive arthritis is an aseptic arthritis caused by an infectious pathogen found outside the joint. Particularly affecting the joints in the lower limbs, the arthritis is usually oligoarticular. In most cases, the condition develops quickly; two to four joints may swell and hurt in an uneven manner within a few days. Inflammatory back pain and dactylitis are also prevalent.

Psoriatic arthritis is known to present in five distinct patterns: oligoarticular (affecting four or fewer joints); polyarticular (affecting five or more joints); prominent distal interphalangeal (DIP) joint involvement; arthritis mutilans; and psoriatic spondylitis. More than 70% of cases follow the oligoarticular pattern. Distal joints are frequently impacted by psoriatic arthritis, which is typically asymmetrical.

Up to 20% of people with inflammatory bowel disease (IBD) develop spondyloarthropathy. Patients with Crohn's disease are more likely to have this association than those with ulcerative colitis. Arthritis may appear before clinical bowel disease. Usually, the lower extremities are asymmetrically affected by arthritis. The arthritis typically manifests abruptly and follows a migratory pattern.

In patients who do not fit the criteria for any of the well-established spondyloarthropathies, the term "undifferentiated spondyloarthropathy" is used to characterize the signs of a spondyloarthropathy. A tiny percentage of these patients eventually experience a clearly characterized spondyloarthropathy, but most experience more general symptoms such as dactylitis, enthesitis, unilateral or alternating buttock pain, inflammatory back pain, and occasionally extra-articular symptoms.

Causes

Spondyloarthritis is caused by a complicated combination of genetic polymorphisms and environment. The relative contributions of genes and environment may differ across different types of spondyloarthritis.[4]

Risk factors

Microscopically visible ileal inflammation is seen in about 50% of people with spondyloarthritis and ankylosing spondylitis during ileocolonoscopy.[5] [6] There seems to be an immunological connection between the gut inflammation observed in Crohn's disease and ankylosing spondylitis. It is known that, in comparison to healthy controls, people with ankylosing spondylitis and those related to them have higher intestinal permeability.[7]

Triggers

The majority of organisms responsible for reactive arthritis are gastrointestinal pathogens, such as Shigella flexneri, Clostridium difficile, Yersinia enterocolitica and Yersinia pseudotuberculosis, Campylobacter jejuni and Campylobacter coli, Salmonella spp. Genitourinary and respiratory infections, such as Chlamydia trachomatis and Chlamydia pneumonia, have also been linked to reactive arthritis.

Genetics

Given the well-established familial aggregation and the concordance rate of up to 63% in identical twins (vs 23% in nonidentical twins), it is evident that genetic variables play a role in the susceptibility to ankylosing spondylitis.[8] [9] There is limited research on familial aggregation in other forms of spondyloarthritis.[10]

HLA-B27 is a polymorphic form of the HLA-B molecule found in up to 95% of ankylosing spondylitis patients of European ancestry,[11] [12]  70% with reactive arthritis,[13] 60% with psoriatic spondylitis,[10] 25% with peripheral psoriatic arthritis,[12] and 70% with spondylitis associated with inflammatory bowel disease.[12] [11]

Mechanism

The arthritogenic-peptide theory is the classic pathophysiological paradigm for spondyloarthritis. It argues that HLA-B27 displays self-peptides that resemble pathogen-derived peptides to CD8-restricted T cells. Two other theories have been proposed to explain HLA-B27's function. They suggest that HLA-B27's genesis may be autoinflammatory rather than autoimmune, as it plays a part in initiating innate immune responses instead of its traditional function of presenting antigens.[14]

According to the first hypothesis, HLA-B27 heavy chains devoid of β2 microglobulin can form disulphide-linked homodimers that are produced at the cell surface and can be recognized directly by KIR3DL2 killer immunoglobulin-like receptors, regardless of the associated peptide.[15] [16]

According to the second hypothesis, the B pocket's Cys 67 residue causes HLA-B27 heavy-chain misfolding in the endoplasmic reticulum before assembling into complexes with peptide and β2 microglobulin.[17] [18] As a result, the unfolded protein response (UPR) modifies the immune cells' cytokine output and reactivity to various innate immunological stimuli.[19] [20] [21]

Diagnosis

Spondyloarthritis is primarily diagnosed, or at least first suspected, based on clinical factors. According to the current criteria for ankylosing spondylitis, the patient must exhibit clinical symptoms of inflammatory back pain and limited spinal mobility together with radiological sacroiliitis. But many people with inflammatory back pain may have no radiographic evidence of sacroiliitis since up to 10 years might pass between the onset of inflammatory back pain and the development of radiographic sacroiliitis.[22] Criteria for the early diagnosis of axial spondyloarthritis have been developed in light of the emergence of effective treatments. These criteria consider the added value of HLA-B27 testing, as well as current advancements in MRI scanning.[23]

Imaging is crucial to the spondyloarthritis diagnosis process. The most distinctive radiographic observation is the sacroiliac (SI) joints' erosion, ankylosis, and sclerosis.[24] There must be clear evidence of sacroiliitis (at least grade 2 bilaterally or grade 3 unilaterally) on the radiographs in order to diagnose ankylosing spondylitis. When axial spondyloarthritis is suspected, sacroiliac joint radiographs are still the initial imaging approach. If radiographs clearly show sacroiliitis, then no more diagnostic imaging is required. But because structural change seen on radiographs can take months or years to emerge, normal radiographs or worrisome abnormalities only warrant additional diagnostic imaging in the context of suggestive clinical symptoms or findings.[25] Furthermore, reading sacroiliac joint radiographs can be difficult and dependent on a number of variables, such as the image quality, the radiological technique, the reader's background, and variations in sacroiliac anatomy.[26] [27]

A challenge associated with radiographic imaging is the typical ten-year lag between the beginning of inflammatory back pain and the development of radiographic sacroiliitis.[23] MRI imaging of the spine and entheses has made it possible to distinguish between inflammatory spinal lesions associated with ankylosing spondylitis and those unrelated to it earlier than is feasible with traditional radiography. It has also allowed for accurate anatomical description of spinal components.[28] The only imaging modality that can precisely identify and evaluate spinal inflammation at this time is magnetic resonance imaging (MRI) of the sacroiliac joints and spine. It is also being developed as a gauge of disease activity and response to treatment.[22]

When evaluating a patient with reactive arthritis or psoriatic arthritis, plain radiographs of the hands and feet are very beneficial. Seventy-five percent of psoriatic arthritis patients have radiographic abnormalities of the peripheral joints, such as soft tissue swelling, erosions, periarticular osteopenia, periostitis, and narrowing of the joint space. Aggressive psoriatic arthritis erosions can result in the articular surface of the proximal bone of the joint being destroyed and taking on the look of a "pencil in cup."[24]

Laboratory abnormalities in spondyloarthritis are nonspecific and less effective for diagnosing a specific disease than clinical presentation. Normochromic normocytic anemia, increased C reactive protein, and erythrocyte sedimentation rate are nonspecific indicators of inflammation that are frequently present in patients.[24]

When patients are carefully chosen, testing for the human leukocyte antigen (HLA) is the most beneficial laboratory investigation. Since only 5% of those with HLA-B27 in the general population will develop ankylosing spondylitis, the correlation between HLA-B27 and the prevalence of spondyloarthritis is weak. Therefore, the illness prevalence in a particular patient population must be taken into account when interpreting results from HLA-B27 testing.[24]

Classification

Spondyloarthritis is classified into two categories based on the Assessment of SpondyloArthritis International Society (ASAS) classification criteria: primarily axial involvement and predominantly peripheral manifestations.[29] [30]

Axial spondyloarthritis

A patient must meet two requirements to be considered for a diagnosis of axial spondyloarthritis: they must be under 45 years old and have experienced back pain of any kind for at least three months.

The second step comprises two sections that are assessed independently according to the existence of either sacroiliitis on imaging or human leukocyte antigen (HLA) B27:

Spondyloarthritis features:

Peripheral spondyloarthritis

The initial requirement is that the patient have at least one of the following three findings:

If the patient meets the previous requirements, they must exhibit at least one of Group A's spondyloarthritis features or two of Group B's spondyloarthritis features.

Group A spondyloarthritis features:

Group B spondyloarthritis features:

Treatment

Improving the patient's state (pain, functional impairment, etc.) and preventing further clinical deterioration are the goals of spondyloarthritis treatment. The ASAS has issued guidelines regarding the use of TNF blockers specifically[32] as well as the general care of spondyloarthritis.[33] Non-steroidal anti-inflammatory drugs (NSAIDs) should be administered first to patients with active, primarily axial signs of spondyloarthritis. If NSAID medication is contraindicated, does not work, or causes side effects, patients should then be treated with tumor necrosis factor (TNF) blockers. Because there is insufficient evidence of treatment efficacy, patients with axial spondyloarthritis who do not exhibit peripheral disease signs are not advised to receive traditional disease-modifying antirheumatic drugs (DMARDs). But in the event that peripheral arthritis is present, patients with spondyloarthritis should get treatment with conventional DMARDs before TNF-blocker medication and after the failure of NSAID therapy.[34]

According to a recent Cochrane systematic review of published work, supervised group physiotherapy is superior to home exercises, individual home-based or supervised exercise programs are preferable to no intervention, and in-patient spondyloarthritis exercise therapy combined with follow-up group physiotherapy is superior to group physiotherapy alone.[35] Recreational exercise, whether performed in a group setting or alone, helps patients with ankylosing spondylitis feel less stiff and in pain. Back exercise also helps these patients function better, but the effects vary depending on how long the disease has been present. Patients' health improves when they engage in back exercises five days a week and recreational activity for at least half an hour each day.[36] [35]

NSAIDs continue to be the first line of treatment for spondylitis, and many patients will get adequate symptom relief on their own with just these medications. The best NSAID for treating patients with ankylosing spondylitis appears to be tolmetin or indomethacin, although there is insufficient evidence to support this theory in rheumatologic practice. The majority of patients with established peptic ulcer disease should take selective COX-2 antagonists.

When peripheral arthritis coexists with axial illness, conventional DMARDs such methotrexate,[37] sulfasalazine,[38] or leflunomide may be useful in treating peripheral spondyloarthritis.[39] These drugs are typically ineffective in treating axial symptoms of spondyloarthritis.[40]

After 2000, a number of studies examining the effects of TNF blockers on patients with ankylosing spondylitis were published. These studies demonstrated that TNF-blocker therapy improves clinical symptoms, CRP levels, and MRI-detectable inflammation in the spine or sacroiliac joints.[34] These improvements were noted with certolizumab pegol,[41] etanercept,[42] [43] infliximab,[44] [45] adalimumab,[46] and golimumab.[47]

Outlook

The lives of people with ankylosing spondylitis are profoundly affected. According to recent statistics, people with ankylosing spondylitis, particularly those who are older and have had the condition longer, may be more likely than population controls to be work handicapped or not engage in the labor market. Additionally, patients with ankylosing spondylitis were more likely to have never married or been divorced. Compared to expectations, women with ankylosing spondylitis were less likely to have had children.[28] Patients with ankylosing spondylitis experience up to 50% more sick leave episodes, an overall 8% loss of productivity, and a thrice higher rate of disability than the general population. Their overall frequency of disability and economic costs are comparable to those of rheumatoid arthritis.[48] Furthermore, increasing evidence indicates that cardiovascular illness puts ankylosing spondylitis patients at risk for early death.[49]

Early research on the course of reactive arthritis indicated a poor prognosis. But more recent research has shown that the prognosis for reactive arthritis is generally favourable.[50] Within six months of onset, the majority of cases seem to resolve.

The prognosis for psoriatic arthritis is worse than previously thought, according to recent research.[51] [52] It has also been demonstrated that psoriatic arthritis patients have a higher mortality rate, which is linked to high erythrocyte sedimentation rate, high usage of medications, and early radiographic damage.

While not well researched, the prognosis for juvenile spondyloarthritisis is unknown.[53] According to the data available, children who have had a condition for longer than five years are more likely to be impaired. After five years of the illness, the chance of remission was only 17 percent. After ten years of the condition, moderate to severe restriction affects around 60% of children with juvenile spondyloarthritisis.

Epidemiology

The prevalence of ankylosing spondylitis and spondyloarthritis in particular varies across populations and is similar to that of HLA-B27. The incidence of spondyloarthritis as a disease entity was only recorded in four investigations, and ranged from 0.48/100,000 in Japan[54] to 62.5/100,000 in Spain.[55] [56] Data on the prevalence of spondyloarthritis were reported from 16 investigations; the results ranged from 0.01% in Japan[54] to 2.5% in Alaska.[57] [56]

Those with European heritage have a 0.2% to 0.7% prevalence of ankylosing spondylitis.[58] [59] [60] Reactive arthritis prevalence is unknown and likely varies with time based on endemic rates of the enteric (Shigella, Salmonella, Campylobacter) and sexually acquired (Chlamydia) infections that cause it. In the general community, 1–3% of people have psoriasis.[60] It is less known how common psoriatic arthritis is, and it is more common in people with more severe disease; population studies in Caucasians suggest that the prevalence is about 0.1%.[58] Inflammatory bowel disease affects 100,000–200,000 Caucasians per 100,000 people, with a male–to–female ratio of 1:1.[59] [58] Those with Asian and African ancestry rarely experience it. Varying reports have varying risks for spondylitis and peripheral arthritis, which may be related to the observer's specialty. Up to 15–20% of people with inflammatory bowel disease have spondylitis. Peripheral arthritis is generally less common in ulcerative colitis patients (up to 10%) than in Crohn's disease patients (up to 20%), while it is more common in cases where a rheumatologist served as the assessor.[59] [58]

History

Moll and associates first proposed the idea of a collection of similar conditions known as seronegative spondarthritides in 1974.[61] Psoriatic arthritis, reactive arthritis, arthritis associated with inflammatory bowel disease, a subtype of juvenile idiopathic arthritis, and ankylosing spondylitis comprise the group of disorders currently referred to as spondyloarthritis.

See also

Further reading

External links

Notes and References

  1. Book: Inman, Robert D. . Goldman's Cecil Medicine . The Spondyloarthropathies . Elsevier . 2012 . 978-1-4377-1604-7 . 10.1016/b978-1-4377-1604-7.00273-6 . 1690–1697.
  2. Sieper . Joachim . Rudwaleit . Martin . Khan . Muhammed Asim . Braun . Jürgen . Concepts and epidemiology of spondyloarthritis . Best Practice & Research Clinical Rheumatology . 20 . 3 . 2006 . 10.1016/j.berh.2006.02.001 . 401–417. 16777573 .
  3. Kataria . Rajesh K. . Brent . Lawrence H. . Spondyloarthropathies . American Family Physician . 69 . 12 . 2004-06-15 . 2853–2860 . 15222650 . 2024-07-24.
  4. Book: Sikora . Keith A. . Layh-Schmitt . Gerlinde . Colbert . Robert A. . Kelley and Firestein's Textbook of Rheumatology . Etiology and Pathogenesis of Spondyloarthritis . Elsevier . 2017 . 978-0-323-31696-5 . 10.1016/b978-0-323-31696-5.00074-7 . 1245–1255.e4.
  5. Leirisalo-Repo . Marjatta . Turunen . Ulla . Stenman . Svante . Helenius . Petri . Seppälä . Kari . High Frequency of Silent Inflammatory Bowel Disease in Spondylarthropathy . Arthritis & Rheumatism . Wiley . 37 . 1 . 1994 . 0004-3591 . 10.1002/art.1780370105 . 23–31. 8129761 .
  6. Mielants . H. . Veys . E. M. . Goemaere . S. . Goethals . K. . Cuvelier . C. . De Vos . M. . Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study . The Journal of Rheumatology . 18 . 10 . 1991 . 0315-162X . 1765980 . 1542–1551.
  7. MARTÍNEZ-GONZÁLEZ . O. . CANTERO-HINOJOSA . J. . PAULE-SASTRE . P. . GÓMEZ-MAGÁN . J. C. . SALVATIERRA-RÍOS . D. . Intestinal Permeability in Patients with Ankylosing Spondylitis and Their Healthy Relatives . Rheumatology . Oxford University Press (OUP) . 33 . 7 . 1994 . 1462-0324 . 10.1093/rheumatology/33.7.644 . 644–647. 8019793 .
  8. Brown . Matthew A. . Kennedy . L. Gail . Macgregor . Alex J. . Darke . Chris . Duncan . Emma . Shatford . Jane L. . Taylor . Andrew . Calin . Andrei . Wordsworth . Paul . Susceptibility to ankylosing spondylitis in twins the role of genes, HLA, and the environment . Arthritis & Rheumatism . Wiley . 40 . 10 . 1997 . 0004-3591 . 10.1002/art.1780401015 . 1823–1828. 9336417 .
  9. Brown . M A . Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis . Annals of the Rheumatic Diseases . BMJ . 59 . 11 . 2000-11-01 . 0003-4967 . 10.1136/ard.59.11.883 . 883–886. 11053066 . 1753017 .
  10. Reveille . John D. . Arnett . Frank C. . Spondyloarthritis: update on pathogenesis and management . The American Journal of Medicine . 118 . 6 . 2005 . 10.1016/j.amjmed.2005.01.001 . 592–603. 15922688 .
  11. Book: van der Linden . Sjef M. . Baeten . Dominique . Maksymowych . Walter P. . Kelley's Textbook of Rheumatology . Ankylosing Spondylitis . Elsevier . 2013 . 978-1-4377-1738-9 . 10.1016/b978-1-4377-1738-9.00075-x . 1202–1220.e5.
  12. Brown . M. A. . Wordsworth . B. P. . Reveille . J. D. . Genetics of ankylosing spondylitis . Clinical and Experimental Rheumatology . 20 . 6 Suppl 28 . 2002 . 0392-856X . 12463446 . S43–49.
  13. P . Ekman . J . Kirveskari . K . Granfors . Modification of disease outcome in Salmonella-infected patients by HLA-B27 . Arthritis and Rheumatism . 2000 . Arthritis Rheum . 43 . 7 . 1527–1534 . 0004-3591 . 10902756 . 10.1002/1529-0131(200007)43:7<1527::AID-ANR17>3.0.CO;2-G . 2024-07-25 .
  14. Dougados . Maxime . Baeten . Dominique . Spondyloarthritis . The Lancet . 377 . 9783 . 2011 . 10.1016/S0140-6736(11)60071-8 . 2127–2137. 21684383 .
  15. Kollnberger . Simon . Bird . Lucy A. . Roddis . Matthew . Hacquard-Bouder . Cecile . Kubagawa . Hiromi . Bodmer . Helen C. . Breban . Maxime . McMichael . Andrew J. . Bowness . Paul . HLA-B27 Heavy Chain Homodimers Are Expressed in HLA-B27 Transgenic Rodent Models of Spondyloarthritis and Are Ligands for Paired Ig-Like Receptors . The Journal of Immunology . The American Association of Immunologists . 173 . 3 . 2004-08-01 . 0022-1767 . 10.4049/jimmunol.173.3.1699 . 1699–1710. 15265899 .
  16. Chan . A. T. . Kollnberger . S. D. . Wedderburn . L. R. . Bowness . P. . Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis . Arthritis & Rheumatism . Wiley . 52 . 11 . 2005-10-27 . 0004-3591 . 10.1002/art.21395 . 3586–3595. 16255049 .
  17. Mear . J. P. . Schreiber . K. L. . Münz . C. . Zhu . X. . Stevanović . S. . Rammensee . H. G. . Rowland-Jones . S. L. . Colbert . R. A. . Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies . Journal of Immunology (Baltimore, Md.: 1950) . 163 . 12 . 1999-12-15 . 0022-1767 . 10586062 . 6665–6670. 10.4049/jimmunol.163.12.6665 .
  18. Dangoria . Nandita S. . DeLay . Monica L. . Kingsbury . Daniel J. . Mear . John P. . Uchanska-Ziegler . Barbara . Ziegler . Andreas . Colbert . Robert A. . HLA-B27 Misfolding Is Associated with Aberrant Intermolecular Disulfide Bond Formation (Dimerization) in the Endoplasmic Reticulum . Journal of Biological Chemistry . Elsevier BV . 277 . 26 . 2002 . 0021-9258 . 10.1074/jbc.m110336200 . 23459–23468. free . 11978783 .
  19. Turner . Matthew J. . Sowders . Dawn P. . DeLay . Monica L. . Mohapatra . Rajashree . Bai . Shuzhen . Smith . Judith A. . Brandewie . Jaclyn R. . Taurog . Joel D. . Colbert . Robert A. . HLA-B27 Misfolding in Transgenic Rats Is Associated with Activation of the Unfolded Protein Response . The Journal of Immunology . The American Association of Immunologists . 175 . 4 . 2005-08-15 . 0022-1767 . 10.4049/jimmunol.175.4.2438 . 2438–2448. 16081815 .
  20. Smith . Judith A. . Turner . Matthew J. . DeLay . Monica L. . Klenk . Erin I. . Sowders . Dawn P. . Colbert . Robert A. . Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-β induction via X-box binding protein 1 . European Journal of Immunology . Wiley . 38 . 5 . 2008-04-18 . 0014-2980 . 10.1002/eji.200737882 . 1194–1203. 18412159 . 2838478 .
  21. DeLay . Monica L. . Turner . Matthew J. . Klenk . Erin I. . Smith . Judith A. . Sowders . Dawn P. . Colbert . Robert A. . HLA–B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats . Arthritis & Rheumatism . Wiley . 60 . 9 . 2009-08-27 . 0004-3591 . 10.1002/art.24763 . 2633–2643. 19714651 . 2893331 .
  22. Book: Reveille, John D. . Clinical Immunology . Spondyloarthritis . Elsevier . 2019 . 978-0-7020-6896-6 . 10.1016/b978-0-7020-6896-6.00057-0 . 769–787.
  23. Taylor . William . Gladman . Dafna . Helliwell . Philip . Marchesoni . Antonio . Mease . Philip . Mielants . Herman . Classification criteria for psoriatic arthritis: Development of new criteria from a large international study . Arthritis & Rheumatism . Wiley . 54 . 8 . 2006-07-26 . 0004-3591 . 10.1002/art.21972 . 2665–2673. 16871531 .
  24. Harper . Brock E. . Reveille . John D. . Spondyloarthritis . Current Sports Medicine Reports . Ovid Technologies (Wolters Kluwer Health) . 8 . 1 . 2009 . 1537-890X . 10.1249/jsr.0b013e3181967ac6 . 29–34. 19142077 . 2898732 .
  25. Poddubnyy . Denis . Rudwaleit . Martin . Early Spondyloarthritis . Rheumatic Disease Clinics of North America . 38 . 2 . 2012 . 10.1016/j.rdc.2012.04.007 . 387–403. 22819091 .
  26. Poddubnyy . D. . Rudwaleit . M. . Haibel . H. . Listing . J. . Marker-Hermann . E. . Zeidler . H. . Braun . J. . Sieper . J. . Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis . Annals of the Rheumatic Diseases . BMJ . 70 . 8 . 2011-05-27 . 0003-4967 . 10.1136/ard.2010.145995 . 1369–1374. 21622969 .
  27. van Tubergen . A . Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? . Annals of the Rheumatic Diseases . BMJ . 62 . 6 . 2003-06-01 . 0003-4967 . 10.1136/ard.62.6.519 . 519–525. 12759287 . 1754576 .
  28. Maksymowych . Walter P. . Inman . Robert D. . Salonen . David . Dhillon . Suhkvinder S. . Williams . Martin . Stone . Millicent . Conner-spady . Barbara . Palsat . Janice . Lambert . Robert G. W. . Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis . Arthritis Care & Research . Wiley . 53 . 5 . 2005-10-05 . 0893-7524 . 10.1002/art.21445 . 703–709. 16208659 .
  29. Rudwaleit . M . van der Heijde . D . Landewe . R . Listing . J . Akkoc . N . Brandt . J . Braun . J . Chou . C T . Collantes-Estevez . E . Dougados . M . Huang . F . Gu . J . Khan . M A . Kirazli . Y . Maksymowych . W P . Mielants . H . Sorensen . I J . Ozgocmen . S . Roussou . E . Valle-Onate . R . Weber . U . Wei . J . Sieper . J . The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection . Annals of the Rheumatic Diseases . BMJ . 68 . 6 . 2009-03-17 . 0003-4967 . 10.1136/ard.2009.108233 . 777–783. 19297344 .
  30. Rudwaleit . M. . van der Heijde . D. . Landewe . R. . Akkoc . N. . Brandt . J. . Chou . C. T. . Dougados . M. . Huang . F. . Gu . J. . Kirazli . Y. . Van den Bosch . F. . Olivieri . I. . Roussou . E. . Scarpato . S. . Sorensen . I. J. . Valle-Onate . R. . Weber . U. . Wei . J. . Sieper . J. . The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general . Annals of the Rheumatic Diseases . BMJ . 70 . 1 . 2010-11-24 . 0003-4967 . 10.1136/ard.2010.133645 . 25–31. 21109520 .
  31. Sieper . J . van der Heijde . D . Landewe . R . Brandt . J . Burgos-Vagas . R . Collantes-Estevez . E . Dijkmans . B . Dougados . M . Khan . M A . Leirisalo-Repo . M . van der Linden . S . Maksymowych . W P . Mielants . H . Olivieri . I . Rudwaleit . M . New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS) . Annals of the Rheumatic Diseases . BMJ . 68 . 6 . 2009-01-15 . 0003-4967 . 10.1136/ard.2008.101501 . 784–788. 19147614 .
  32. Braun . J . First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis . Annals of the Rheumatic Diseases . BMJ . 65 . 3 . 2006-03-01 . 0003-4967 . 10.1136/ard.2005.040758 . 316–320. 16096329 . 1798064 .
  33. Zochling . J . ASAS/EULAR recommendations for the management of ankylosing spondylitis . Annals of the Rheumatic Diseases . BMJ . 65 . 4 . 2006-04-01 . 0003-4967 . 10.1136/ard.2005.041137 . 442–452. 16126791 . 1798102 .
  34. Sieper . Joachim . Poddubnyy . Denis . New evidence on the management of spondyloarthritis . Nature Reviews Rheumatology . 12 . 5 . 2016 . 1759-4790 . 10.1038/nrrheum.2016.42 . 282–295. 27052489 .
  35. Dagfinrud . Hanne . Hagen . Kåre Birger . Kvien . Tore K . Physiotherapy interventions for ankylosing spondylitis . Cochrane Database of Systematic Reviews . Wiley . 2009 . 2 . 2008-01-23 . CD002822 . 1465-1858 . 10.1002/14651858.cd002822.pub3 . 18254008 . 8453259 .
  36. Uhrin . Zuzana . Kuzis . Susana . Ward . Michael M. . Exercise and Changes in Health Status in Patients With Ankylosing Spondylitis . Archives of Internal Medicine . American Medical Association (AMA) . 160 . 19 . 2000-10-23 . 2969–2975 . 0003-9926 . 10.1001/archinte.160.19.2969 . 11041905 .
  37. Haibel . H . Brandt . H C . Song . I H . Brandt . A . Listing . J . Rudwaleit . M . Sieper . J . No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial . Annals of the Rheumatic Diseases . BMJ . 66 . 3 . 2007-03-01 . 0003-4967 . 10.1136/ard.2006.054098 . 419–421. 16901959 . 1856012 .
  38. Chen . Junmin . Lin . Shaopeng . Liu . Chao . Sulfasalazine for ankylosing spondylitis . Cochrane Database of Systematic Reviews . Wiley . 2014 . 11 . 2014-11-27 . CD004800 . 1465-1858 . 10.1002/14651858.cd004800.pub3 . 25427435 . 11182569 .
  39. Haibel . H . Six months open label trial of leflunomide in active ankylosing spondylitis . Annals of the Rheumatic Diseases . BMJ . 64 . 1 . 2005-01-01 . 0003-4967 . 10.1136/ard.2003.019174 . 124–126. 15608310 . 1755172 .
  40. Braun . J . van den Berg . R . Baraliakos . X . Boehm . H . Burgos-Vargas . R . Collantes-Estevez . E . Dagfinrud . H . Dijkmans . B . Dougados . M . Emery . P . Geher . P . Hammoudeh . M . Inman . RD . Jongkees . M . Khan . MA . Kiltz . U . Kvien . TK . Leirisalo-Repo . M . Maksymowych . WP . Olivieri . I . Pavelka . K . Sieper . J . Stanislawska-Biernat . E . Wendling . D . Özgocmen . S . van Drogen . C . van Royen . BJ . van der Heijde . D . 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis . Annals of the Rheumatic Diseases . BMJ . 70 . 6 . 2011-05-02 . 0003-4967 . 10.1136/ard.2011.151027 . 896–904. 21540199 . 3086052 .
  41. Landewé . R . Braun . J . Deodhar . A . Dougados . M . Maksymowych . W P . Mease . P J . Reveille . J D . Rudwaleit . M . van der Heijde . D . Stach . C . Hoepken . B . Fichtner . A . Coteur . G . de Longueville . M . Sieper . J . Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study . Annals of the Rheumatic Diseases . BMJ . 73 . 1 . 2013-09-06 . 0003-4967 . 10.1136/annrheumdis-2013-204231 . 39–47. 24013647 . 3888598 .
  42. Davis . John C. . Van Der Heijde . Désirée . Braun . Jurgen . Dougados . Maxime . Cush . John . Clegg . Daniel O. . Kivitz . Alan . Fleischmann . Roy . Inman . Robert . Tsuji . Wayne . Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial . Arthritis & Rheumatism . Wiley . 48 . 11 . 2003 . 0004-3591 . 10.1002/art.11325 . 3230–3236. 14613288 .
  43. Davis . J C . Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks . Annals of the Rheumatic Diseases . BMJ . 64 . 11 . 2005-08-26 . 0003-4967 . 10.1136/ard.2004.035105 . 1557–1562. 15843448 . 1755272 .
  44. Braun . J . Brandt . J . Listing . J . Zink . A . Alten . R . Golder . W . Gromnica-lhle . E . Kellner . H . Krause . A . Schneider . M . Sörensen . H . Zeidler . H . Thriene . W . Sieper . J . Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial . The Lancet . Elsevier BV . 359 . 9313 . 2002 . 0140-6736 . 10.1016/s0140-6736(02)08215-6 . 1187–1193. 11955536 .
  45. van der Heijde . Désirée . Dijkmans . Ben . Geusens . Piet . Sieper . Joachim . DeWoody . Kimberly . Williamson . Paul . Braun . Jürgen . Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT) . Arthritis & Rheumatism . Wiley . 52 . 2 . 2005 . 0004-3591 . 10.1002/art.20852 . 582–591. 15692973 .
  46. van der Heijde . Désirée . Kivitz . Alan . Schiff . Michael H. . Sieper . Joachim . Dijkmans . Ben A. C. . Braun . Jürgen . Dougados . Maxime . Reveille . John D. . Wong . Robert L. . Kupper . Hartmut . Davis . John C. . Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial . Arthritis & Rheumatism . Wiley . 54 . 7 . 2006-06-27 . 0004-3591 . 10.1002/art.21913 . 2136–2146. 16802350 .
  47. Inman . Robert D. . Davis . John C. . Heijde . Désirée Van Der . Diekman . Laura . Sieper . Joachim . Kim . Sung Il . Mack . Michael . Han . John . Visvanathan . Sudha . Xu . Zhenhua . Hsu . Benjamin . Beutler . Anna . Braun . Jürgen . Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial . Arthritis & Rheumatism . Wiley . 58 . 11 . 2008-10-30 . 0004-3591 . 10.1002/art.23969 . 3402–3412. 18975305 .
  48. Boonen . Annelies . Brinkhuizen . Tjinta . Landewé . Robert . van der Heijde . Désirée . Severens . Johan L . Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost . Annals of the Rheumatic Diseases . BMJ . 69 . 6 . 2010-05-03 . 0003-4967 . 10.1136/ard.2009.116764 . 1123–1128. 20439293 .
  49. Szabo . Shelagh M. . Levy . Adrian R. . Rao . Sumati R. . Kirbach . Stephanie E. . Lacaille . Diane . Cifaldi . Mary . Maksymowych . Walter P. . Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population-based study . Arthritis & Rheumatism . Wiley . 63 . 11 . 2011-10-28 . 0004-3591 . 10.1002/art.30581 . 3294–3304. 21834064 .
  50. Sairanen . Eero . Paronen . Ilmari . Mähönen . Heikki . Reiter's Syndrome: A Follow-Up Study . Acta Medica Scandinavica . 185 . 1–6 . 1969-01-12 . 0001-6101 . 10.1111/j.0954-6820.1969.tb07298.x . 57–63. 5805970 .
  51. Lee . W. . Reveille . J. D . Davis . J. C . Learch . T. J . Ward . M. M . Weisman . M. H . Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort . Annals of the Rheumatic Diseases . BMJ . 66 . 5 . 2007-05-01 . 0003-4967 . 10.1136/ard.2006.060293 . 633–638. 17127685 . 1954622 .
  52. Gladman . Dafna D. . Chandran . Vinod . Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future? . Current Rheumatology Reports . Springer Science and Business Media LLC . 13 . 4 . 2011-04-15 . 1523-3774 . 10.1007/s11926-011-0182-x . 346–352.
  53. Colbert . Robert A. . Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond . Nature Reviews Rheumatology . Springer Science and Business Media LLC . 6 . 8 . 2010-07-06 . 1759-4790 . 10.1038/nrrheum.2010.103 . 477–485. 20606622 . 2994189 .
  54. Hukuda . S. . Minami . M. . Saito . T. . Mitsui . H. . Matsui . N. . Komatsubara . Y. . Makino . H. . Shibata . T. . Shingu . M. . Sakou . T. . Shichikawa . K. . Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society . The Journal of Rheumatology . 28 . 3 . 2001 . 0315-162X . 11296958 . 554–559.
  55. Muñoz-Fernández . S. . de Miguel . E. . Cobo-Ibáñez . T. . Carmona . L. . Steiner . M. . Descalzo . M. A. . Ferreira . A. . Balsa . A. . Martín-Mola . E. . ESPIDEP Study Group . Early spondyloarthritis: results from the pilot registry ESPIDEP . Clinical and Experimental Rheumatology . 28 . 4 . 2010 . 0392-856X . 20659413 . 498–503.
  56. Stolwijk . Carmen . Boonen . Annelies . van Tubergen . Astrid . Reveille . John D. . Epidemiology of Spondyloarthritis . Rheumatic Disease Clinics of North America . 38 . 3 . 2012 . 23083748 . 4470267 . 10.1016/j.rdc.2012.09.003 . 441–476.
  57. Boyer . G. S. . Templin . D. W. . Cornoni-Huntley . J. C. . Everett . D. F. . Lawrence . R. C. . Heyse . S. F. . Miller . M. M. . Goring . W. P. . Prevalence of spondyloarthropathies in Alaskan Eskimos . The Journal of Rheumatology . 21 . 12 . 1994 . 0315-162X . 7699631 . 2292–2297.
  58. Stolwijk . Carmen . van Onna . Marloes . Boonen . Annelies . van Tubergen . Astrid . Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis . Arthritis Care & Research . Wiley . 68 . 9 . 2016-07-27 . 2151-464X . 10.1002/acr.22831 . 1320–1331. 26713432 .
  59. Loftus . Edward V . Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences . Gastroenterology . Elsevier BV . 126 . 6 . 2004 . 0016-5085 . 10.1053/j.gastro.2004.01.063 . 1504–1517. 15168363 .
  60. Thom . Nicole . Ritchlin . Christopher T. . Zhang . Xiao . Reveille . John . Weisman . Michael H. . Prevalence of Chronic Axial Pain, Inflammatory Back Pain, and Spondyloarthritis in Diagnosed Psoriasis . Arthritis Care & Research . Wiley . 67 . 6 . 2015 . 2151-464X . 10.1002/acr.22528 . 829–835. 25469666 . 4488898 .
  61. MOLL . J M H . HASLOCK . IAN . MACRAE . I F . WRIGHT . V . ASSOCIATIONS BETWEEN ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS, REITERʼS DISEASE, THE INTESTINAL ARTHROPATHIES, AND BEHCETʼS SYNDROME . Medicine . Ovid Technologies (Wolters Kluwer Health) . 53 . 5 . 1974 . 0025-7974 . 10.1097/00005792-197409000-00002 . 343–364. 4604133 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Spondyloarthritis".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.